Jim Tananbaum

Dr. Tananbaum is the founding CEO of Foresite Capital Management. He has led investments in 21 successful healthcare companies, including Amira Pharmaceuticals (acquired by Bristol-Myers Squibb), Amerigroup and Jazz Pharmaceuticals. Previously, Dr. Tananbaum founded and held management positions at GelTex Pharmaceuticals (acquired by Genzyme for $1.6B) and Theravance. He holds an M.D. from Harvard Medical School and an M.B.A from Harvard Business School, and a B.S. and B.S.E.E. from Yale University. Dr. Tananbaum has served on the advisory boards and/or visiting committees to the Harvard-MIT HST program and Yale School of Engineering.